Treats Major Depressive Disorder. ANDA 201336, held by Heritage. Fluoxetine Hydrochloride.
As of Nov 16, 2026, ANDA 201336 (Fluoxetine Hydrochloride), held by Heritage, was first approved by FDA on Oct 1, 2012, with 5 approved supplements and 0 published complete response letters.
Fluoxetine Capsules are indicated for the treatment of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 1, 2012 | Original application | Approved | None posted |
| Fluoxetine HydrochlorideEQ 10MG BASE · capsule;oral | Fluoxetine Hydrochloride | Rx |
| Fluoxetine HydrochlorideEQ 20MG BASE · capsule;oral | Fluoxetine Hydrochloride | Rx |
| Fluoxetine HydrochlorideEQ 40MG BASE · capsule;oral | Fluoxetine Hydrochloride | Rx |
| Jul 20, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 20, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jul 20, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jul 20, 2020 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jul 20, 2020 | Supplement 5Labeling · Standard review | Approved | None posted |
| Oct 1, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters